Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE 2025 Interim Report

Time:2025-08-22

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization for Drugs

Time:2025-08-15

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Achievement of The Primary Endpoint In Phase III Clinical Trials of Recombinant Anti-Human Il-17aF Humanized Monoclonal Antibody Injection

Time:2025-07-21

Ad hoc announcement pursuant to Art. 53 LR-Announcement on the Implementation of 2024 Profit Distribution of JCARE

Time:2025-07-10

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2025-06-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2025-06-19

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 Annual General Meeting

Time:2025-06-06

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Proposed Acquisition of Equity Interests in Vietnam IMP by Controlled Subsidiary Livzon Group

Time:2025-05-22

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Aripiprazole Microspheres for Injection

Time:2025-05-09

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2025 First Extraordinary General Meeting

Time:2025-05-09

< 1234...12 >